

Received Date : 14-Mar-2016

Revised Date : 04-May-2016

Accepted Date : 14-Jun-2016

Article type : Regular Manuscript

Title of the paper: Association of low ficolin-lectin pathway parameters with Cardiac Syndrome X

Running title: Lectin pathway parameters in Cardiac Syndrome X

Authors: Zsófia Horváth^{a,c,1}, Dorottya Csuka^{b,1}, Katarina Vargova^c, Sarolta Leéc, Lilian Varga^b, Peter Garred^d, István Préda^{a,c}, Emese Tóth Zsámboki^c, Zoltán Prohászka^b, Róbert Gábor Kiss^{a,c}

^aResearch Group for Inflammation Biology and Immunogenomics of Hungarian Academy of Sciences and Semmelweis University, Robert Károly krt. 44, 1134 Budapest, Hungary

^b3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary

^cHungarian Defence Forces, Medical Centre, Department of Cardiology, Róbert Károly krt. 44, 1134 Budapest, Hungary

^dLaboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

¹These authors contributed equally to their work

Corresponding author:

Zsófia Horváth, MD

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/sji.12454

This article is protected by copyright. All rights reserved.

Hungarian Defence Forces, Medical Centre, Department of Cardiology,

Róbert Károly krt. 44, 1134 Budapest, Hungary

Telephone number: +3620/411-79-29

Fax number: +361/465-1857

horvzsofi@hotmail.com

Clinical Immunology

Summary

In patients with typical angina pectoris, inducible myocardial ischaemia and macroscopically normal coronaries (Cardiac Syndrome X, CSX) significantly elevated plasma level of terminal complement complex (TCC), the common end-product of complement activation, has been observed without subsequent activation of the classical or the alternative pathways. Therefore, our aim was to clarify the role of the ficolin-lectin pathway in CSX. Eighteen CSX patients, 37 stable angina patients with significant coronary stenosis (CHD) and 54 healthy volunteers (HC) were enrolled. Serum levels of ficolin-2, ficolin-3, ficolin-3/MASP-2 complex and ficolin-3 mediated TCC deposition (FCN3-TCC) were determined. Plasma level of TCC was significantly higher in CSX than in HC or in CHD groups (5.45 vs. 1.30 vs. 2.04AU/ml, $p<0.001$). Serum levels of ficolin-2 and ficolin-3 were significantly lower in CSX compared to HC or to CHD groups (3.60 vs. 5.80 or 5.20 μ g/ml, $p<0.05$; 17.80 vs. 24.10 or 26.80 μ g/ml, $p<0.05$). The ficolin-3/MASP-2 complex was significantly lower in CSX group compared to HC (92.90 vs. 144.90AU/ml, $p=0.006$). FCN3-TCC deposition was significantly lower in the CSX group compared to HC and to CHD (67.8% vs.143.3% or 159.7%, $p<0.05$). In the CSX group, significant correlation was found between TCC and FCN3-TCC level ($r=0.507$, $p=0.032$) and ficolin-3/MASP-2 complex level and FCN3-TCC deposition ($r=0.651$, $p=0.003$). In conclusion, in patients with typical angina and myocardial ischemia despite macroscopically normal coronary arteries, low levels of several lectin-pathway parameters were observed, indicating complement activation and consumption. Complement activation through the ficolin-lectin pathway might play a role in the complex pathomechanism of CSX.

Introduction

Our understanding of coronary syndromes has evolved in the last two decades from the paradigm of obstructive atherosclerosis of epicardial coronary arteries into the complex concept of anatomic-functional abnormalities of coronary microcirculation. Under normal physiological conditions, the coronary microcirculation regulates myocardial perfusion in response to increased demand by endothelial-dependent and -independent mechanisms [1].

Patients with typical angina pectoris and inducible myocardial ischaemia, but with macroscopically healthy coronaries has become commonly known as “Cardiac Syndrome X” (CSX, with incidence of 19 % in men and up to 48 % in women) [2, 3]. As an underlying pathomechanism, microvascular angina characterized by reduced coronary microvascular dilatory responses and increased coronary resistance has been suggested and consistently found in CSX patients [4]. In stable angina patients with proven myocardial ischemia and normal coronary arteries, significantly increased risks of future major adverse cardiac events and all-cause mortality was found compared to a normal population without ischemic heart disease, even after adjusting for traditional cardiac risk factors [3, 4]. Although obvious explanation - namely endothelial dysfunction and other microvascular abnormalities in both coronary and peripheral arteries - has been suggested a decade ago, the complex pathomechanism has remained undetermined [5-8]. Taken together, stable angina patients with normal coronary arteries should be recognized as a unique clinical entity [9].

Data about the role of complement system in angina patients with macroscopically normal coronary arteries are lacking. As previously published [10], the level of terminal soluble C5b-9 complex (TCC) was increased in plasma of this patient group compared to those with angiographically proven coronary atherosclerosis. In these patients, despite the lacking morphologically evident atherosclerotic lesions, complement system activation seems to be present.

The complement system can be activated *via* three different routes, namely by the classical, the alternative, or the lectin pathways [11, 12]. The lectin pathway is triggered by the binding of mannose binding lectin (MBL) or ficolins to special carbohydrate structures on the surface of microorganisms, apoptotic cells or altered-self structures [13]. In humans, five initiation molecules of the lectin pathway have been described: MBL, the recently recognized ficolin-1 (M-ficolin), ficolin-2 (L-ficolin), ficolin-3 (H-ficolin or Hakata antigen) and lately also collectin-11 [14-16]. While ficolin-1 can be predominantly found intracellularly in leukocytes, ficolin-2 and ficolin-3 can be found mainly in serum [17]. MBL and ficolins in serum are complexed with MBL/ficolin-associated serine proteases (MASPs – ie, MASP-1, MASP-2, or MASP-3) and their truncated proteins (sMAP and MAP-1) [16, 18, 19]. The initiation of the lectin pathway finally results in the formation of terminal pathway

activation complex (TCC or C5b-9), similarly to the previously mentioned classical, or alternative pathways. Importantly, MASPs can activate C4 and C2 leading to the generation of C3-convertase (C4b2b) of the complement classical and lectin pathways [13, 19].

As we published previously [10], the high C1rC1sC1-INH level (observed in patients with significant coronary atherosclerosis) was an independent biomarker of ischaemic heart disease. In this study, the level of TCC was increased in patients with macroscopically healthy coronary arteries compared to those with angiographically proven coronary atherosclerosis. Since no parallel activation of the classical, or the alternative complement pathway was observed in this study, our findings indicated the potential involvement of the lectin pathway in the CSX patient population. Based on these results, our aim was to clarify the role of lectin pathway activation and ficolins in the CSX patient cohort.

Materials and Methods

Patient population

In this case-control study we enrolled 55 patients scheduled for elective coronary angiography at our institution with diagnosis of stable angina pectoris. In each patient, non-invasive tests (exercise stress test, or myocardial perfusion scan) were performed before coronary angiography and were positive for inducible myocardial ischemia. The coronary angiography showed macroscopically normal coronary arteries, despite the history of typical angina and positive ischemia provocation non-invasive tests in 18 patients (CSX group). In 37 patients angiography indicated significant coronary artery stenosis (coronary heart disease: CHD group). These patients were referred to percutaneous coronary intervention, or to coronary artery bypass graft (CABG) surgery or were advised for conservative therapy. The cohort of stable angina patients was examined in a previous study, determining classical and alternative pathways of complement activation [10]. 54 healthy volunteers served as control (HC group).

Blood samples

In each patient, 8 ml of venous blood was drawn from the cubital vein into serum-separating tubes before coronary angiography. Peripheral blood samples were drawn from healthy subjects similarly. The serum was separated by centrifugation at 3000 rpm for 10 minutes at room temperature. The samples were immediately frozen at -80 °C in aliquots, and were thawed only before the

Accepted Article
measurement of lectin pathway parameters. Patient exclusion criteria were as follows: acute coronary syndrome, cardiogenic shock, history of severe renal or hepatic disease, hematological disorders, acute or chronic inflammatory disease and malignancy. The study protocol was approved by both the institutional review board of Semmelweis University of Budapest and the Hungarian Defence Forces Medical Centre. Informed consent was obtained in accordance with the Declaration of Helsinki.

Measurement of the lectin pathway parameters

The concentrations of ficolin-2 [20], ficolin-3 [21], the ficolin-3/MASP-2 complex [22], MAP-1 [23] and sC5b-9 (TCC) [10] were determined by previously described standard sandwich ELISA techniques, using monoclonal antibodies specific for each molecule. Biotinylated antibodies were added to the second layer, and streptavidin/HRP complexes were used for detection. All samples were tested in duplicate against a standard serum pool with known content of each analyte. Ficolin-3-mediated terminal complement complex deposition (FCN3-TCC) was measured as described previously by Hein et al. [24]. In brief, acetylated bovine serum albumin (acBSA) was immobilized in Maxisorb ELISA plates and used as a ficolin-3 ligand. In order to block any interference from the classical pathway or the alternative pathway [25], full serum samples were pre-incubated with sodium polyanethole sulfonate (SPS). Serum samples were diluted 1:25 in barbital buffer containing 0.05% Tween-20 (VBS-T), and incubated on the plate for 45 minutes at 37 °C. Thereafter, mouse-anti-human TCC was applied for 2 hours at room temperature and then, rabbit-anti-mouse-HRP was added to the wells as secondary antibody, for 1 hour at 37 °C. Finally, the plates were developed using OPD substrate and the optical density was determined at 490/630 nm by ELISA reader (BioTek).

Statistical analysis

The statistical calculations were performed with Prism for Windows v5.02 (GraphPad Software Inc., San Diego, CA, www.graphpad.com), and SPSS v13.0 (SPSS Inc., Chicago, IL). Since most of the variables were non-Gaussian, non-parametric tests were applied. Mann–Whitney's U-test was used to compare two independent groups. Spearman rank correlation analysis was performed to analyze correlation between continuous variables. All the statistical analyses were two-tailed, and $p < 0.05$ was considered to represent a significant difference.

Results

Demographic data

Demographic data of the CSX and CHD populations are presented in Table 1. The 54 healthy volunteers (21 men and 33 women, median age: 33 years, 25th–75th percentiles: 21–58 years) did not have any known disease. Within the healthy control group, age and BMI ($p < 0.0001$ for both comparisons) were significantly lower, compared to CSX and CHD groups, respectively.

Both patient groups had increased presence of conventional cardiovascular risk factors, such as hypertension, type-2 diabetes mellitus, hyperlipidaemia, obesitas, previous cardiovascular event and tobacco use. The majority of the patients received antiplatelet therapy, ACE - inhibitor, beta-blocker, statin, or nitrate. No significant difference was found regarding medical therapy upon admission between patients groups (Table 1). Compared to CSX patients, significantly higher incidence of previous myocardial infarction ($p = 0.003$, Fisher's exact test) and percutaneous coronary intervention ($p = 0.003$, Fisher's exact test) was observed in the CHD group. Interestingly, there were no significant differences in body mass index, both groups were in the "overweight" category. The HDL-cholesterol level was significantly higher in CSX patients, compared to CHD patients ($p = 0.013$, Mann–Whitney's U-test).

When comparing laboratory parameters, we found no significant differences in kidney or liver function parameters between the patient groups.

Serum and plasma levels of lectin pathway components

The plasma level of TCC, the common end product of the complement activation pathways, was significantly higher in the CSX group compared to CHD and to HC (5.45 AU/ml vs. 2.04 AU/ml, $p = 0.0001$; 5.45 AU/ml vs. 1.30, $p < 0.0001$) (Table 2). These data represent a subgroup analysis of our previously published results [10].

The serum levels of ficolin-2 were significantly lower in CSX group compared to HC (3.60 $\mu\text{g/ml}$ vs. 5.80 $\mu\text{g/ml}$, $p = 0.005$) and also lower compared to CHD group (3.60 $\mu\text{g/ml}$ vs. 5.20 $\mu\text{g/ml}$, $p = 0.052$). Similarly, the serum levels of ficolin-3 were significantly lower in CSX group compared to HC (17.80 $\mu\text{g/ml}$ vs. 24.10 $\mu\text{g/ml}$, $p = 0.035$) and to CHD (17.80 $\mu\text{g/ml}$ vs. 26.80 $\mu\text{g/ml}$, $p = 0.016$), as well (Table 2).

The ficolin-3/MASP-2 complex was significantly lower in CSX group compared to HC (92.90 AU/ml vs. 144.90 AU/ml, $p=0.006$). Interestingly, the ficolin-3/MASP-2 complex was also significantly lower in the CHD group compared to HC (87.0 AU/ml vs. 144.90 AU/ml, $p=0.011$).

The FCN3-TCC deposition was significantly lower in the CSX group compared to HC (67.8 % vs. 143.3 %, $p=0.008$) and to CHD (67.8 % vs. 159.7 %, $p=0.037$), as well. There were no significant differences in serum MAP-1 levels, however, the levels tended to be the lowest in the CSX group (CSX: 178.60 ng/ml, HC: 194.50 ng/ml, CHD: 212.40 ng/ml) (Table 2).

Correlations between serum lectin pathway parameters in the CSX group

We found significant correlation between TCC and FCN3-TCC in the CSX group ($r=0.507$, $p=0.032$) (Figure 1/A). Similarly, the ficolin-3/MASP-2 complex level and FCN3-TCC deposition correlated significantly ($r=0.651$, $p=0.003$) (Figure 1/B).

Cardiovascular risk factors and serum lectin pathway components

When analyzing the total patient cohort ($n=55$), significantly higher TCC level (5.04 AU/ml vs. 2.05 AU/ml, $p=0.0002$) was observed in non-smoking individuals compared to smoking patients. Presence of hypertension or diabetes mellitus, similarly to age, body-mass index, kidney and liver function parameters and CRP were not associated with the measured lectin pathway parameters.

Importantly, among cardiovascular risk factors, patients with hyperlipidemia had significantly different levels of lectin pathway products. Ficolin-2, ficolin-3, ficolin-3/MASP-2 complex and FCN3-TCC deposition was significantly higher within hyperlipidaemic CHD patients (Table 3). Remarkably, this phenomenon was not observed in the CSX group (Table 3).

Further evaluating hyperlipidaemic patients, we analyzed the serum lectin pathway parameters in respect to serum cholesterol and triglyceride levels. When Spearman rank test was performed, serum lectin pathway component levels showed no significant correlation with serum cholesterol values. In contrast, we found significant correlation with ficolin-2, ficolin-3, ficolin-3/MASP-2 complex, FCN3-TCC deposition and MAP-1 levels and serum triglyceride levels in the CHD group (Table 4). It's important to note, that such correlations were absent in the CSX group.

Medical therapy and serum lectin pathway parameters

Intake of acetylsalicylic acid, ACE-inhibitors, beta-blockers and lipid-lowering agents were not associated with the measured lectin pathway parameters (data not shown).

Patients on chronic clopidogrel therapy had significantly higher ficolin-3/MASP-2 complex (121.67 AU/ml vs 73.50 AU/ml, $p=0.015$) and ficolin-3 (30.40 $\mu\text{g/ml}$ vs. 16.60 $\mu\text{g/ml}$, $p=0.006$) levels in the CSX subgroup, when compared to patients without such therapy. Similar phenomenon was not observed in the CHD group.

Discussion

Cardiac syndrome X remains a major diagnostic and therapeutic challenge causing significant deterioration in patient's functioning and quality of life. Although substantial data report microvascular and endothelial dysfunction within this patient group, the complex pathomechanism is still unclear.

In the present study we have demonstrated consumption of multiple parameters along the ficolin-lectin pathway. We observed significantly lower serum levels of ficolin-2, ficolin-3, ficolin-3/MASP-2 complex and FCN3-TCC deposition accompanied by significantly higher TCC level in CSX patients compared to healthy controls and to patients with angiographically proven coronary heart disease. Furthermore, we found significant correlations between TCC and FCN3-TCC deposition, ficolin-3/MASP-2 complex level and FCN3-TCC deposition.

According to these results, in the group of CSX patients consumption and activation of the ficolin-lectin pathway is present, best marked by low levels of ficolin-2 and ficolin-3. We consider lower ficolin-3/MASP-2 complex levels as a consequence of the decreased level of the ficolin-3 component. Measurement of the FCN3-TCC, where the serum is activated with a ficolin-3 specific activator agent and the induced TCC-formation is analyzed is indicative for the remaining activity of the pathway. Decreased ficolin-3 mediated TCC-deposition is therefore a sign of prior *in vivo* activation and consumption of the ficolin-lectin pathway.

Lectin pathway activation appears to have a controversial role in the cardiovascular system. While several studies pointed to a beneficial effect of the lectin pathway activation resulting in anti-atherosclerotic effect [26, 27], others showed adverse cardiovascular effects of high MBL plasma concentration [28]. MASPs were associated with cardiovascular risk factors including dyslipidemia, obesity, and hypertension in patients with stable coronary artery disease [29]. Furthermore, MASP-2

plasma level was lower in myocardial infarction and stroke patients compared to stable coronary artery disease [29]. In a magnetic resonance study, ficolin-2, MBL and MAP-1 were associated with left ventricle dilatation after myocardial infarction indicating a potential role for lectin pathway products in myocardial remodeling [30].

Although our results suggest changes in lectin pathway complement cascade in CSX patients, our data can not verify causality between the measured parameters and pathogenesis of CSX. There is a general agreement, that the main pathological feature in the majority of CSX patients is microvascular/endothelial dysfunction [31]. *Dollard et al.* demonstrated that C-reactive protein (CRP) remains significantly higher in CSX patients who remain symptomatic than in either healthy controls [32]. Furthermore, coronary endothelial dysfunction may be associated with an increased release of constricting factors and the production of pro-inflammatory cytokines, cell adhesion molecules and growth factors (i.e. intracellular cell adhesion molecule-1 and vascular cell adhesion molecule-1). Inflammatory and proliferative changes in the vessel wall might cause arteriole hyperplasia and perivascular fibrosis leading to microvascular dysfunction [33, 34, 35].

Several members of the complement system were found to be deposited in the microvascular system of diabetic patients (glomeruli and glomerular capillaries [36], retinal vessels [37] and choriocapillaries [38]). Based on our findings, namely the significantly lower serum levels of the ficolin-2, the ficolin-3, the ficolin-3/MASP-2 complex, we hypothesize that lectin-pathway product deposition might also occur in the subendothelial matrix and contribute to microvascular dysfunction. Besides, these activated molecules might bind to pathological structures on the surface of endothelial cells. It was described, that ficolins recognizes acetyl-group containing substances including N-acetylglucosamine [39, 40] and glucan [41]. Furthermore, in addition to sugars, they also could bind to substances such as elastin and DNA [18]. An intact endothelium is a fully biocompatible surface that is not recognized by the complement system. However, blood contact with a damaged endothelium will lead to a certain degree of activation of the complement system [42].

The end product of the complement activation, composed of components C5b, C6, C7, C8 and C9, called terminal complement complex C5b-9 (TCC), or “membrane attack complex” (MAC). TCC facilitates the killing of bacteria and other pathogens by altering the permeability of their membranes. TCC was initially considered to be involved mainly in cytolytic processes of either pathogenesis or host cells [11]. Endothelial cells represent a potential target of TCC, which exerts a number of non-cytolytic effects [43]. *Hoffmeister et al.* described elevated C5b-9 levels in stable angina patients compared to healthy individuals [44]. Furthermore, in patients with acute coronary

syndromes the C5b-9 levels were even higher [44]. Our data are in agreement with these observations; TCC levels were lowest in healthy controls and significantly elevated in the CHD group. Interestingly, TCC levels were the highest in CSX patients. Excess amount of this membrane-attack complex might have a direct cytolytic effect on endothelial cells, contributing to the well-documented above described endothelial dysfunction in these patients.

There are several potential triggers of microvascular dysfunction, including many of the conventional cardiac risk factors such as hypertension, dyslipidemia and smoking [45]. Triglyceride levels correlated significantly with all the lectin pathway components in CHD but not in CSX patients. One can speculate, that the well-known relationship between high serum lipid levels, lipid accumulation and atherosclerotic plaques is absent in these patients.

Emerging evidence suggests that platelets may have an ability to interact with both the classical and alternative pathway of complement activation [46]. Our results indicate that medical therapy with the platelet ADP receptor inhibitor clopidogrel was associated with the lack of ficolin-lectin pathway consumption in CSX patients. Clopidogrel have a pleiotropic, anti-inflammatory and immune response/modulating effect, and might influence the lectin pathway of the complement system as well. However, low number of individuals on chronic clopidogrel therapy in the CSX cohort was inadequate to further analyze the complex effect.

MBL, similarly to ficolins is a pattern recognition molecule and is an upstream component of the lectin pathway complement cascade [11, 12]. High level of MBL was found in ST-elevation myocardial infarction patients with reduced left ventricular systolic function [47]. Elevated MBL level was shown to be a risk factor for future development of coronary heart disease in healthy men [28]. In contrast, in a large prospective study high MBL level was associated with decreased risk of myocardial infarction independently of other cardiovascular factors [48]. Furthermore, MBL deficiency- associated genotypes were linked to increased early incidence of myocardial infarction [49]. Taken together, the role of MBL in the development of cardiovascular disease and/or prognosis is controversial and data regarding angina patients with macroscopically normal coronaries are completely missing. In the future, determination of the MBL level might be relevant in Cardiac syndrome X patients.

In summary, we demonstrate significantly lower serum levels of lectin-pathway parameters, namely ficolin-2, ficolin-3, ficolin-3/MASP-2 complex and FCN3-TCC deposition and significantly higher TCC levels in CSX patients compared to healthy controls or to angiographically proven coronary heart disease patients. Low levels of several lectin-pathway products might reflect upstream consumption and consequent, downstream terminal complement complex activation. As

we hypothesized, complement activation might contribute to the increased cardiovascular risk of CSX patients by promoting endothelial and microvascular dysfunction. The topic of complement system activation via the lectin pathway requires further evaluation in a larger patient cohort with cardiac syndrome X.

Acknowledgements

We dedicate this work to the memory of Professor George Füst MD, DSc, who largely stimulated the planning and execution of this study but tragically passed away before the submission of the manuscript.

The authors wish to thank Mr Jesper Andresen for excellent technical assistance. We are also greatly indebted for the expert technical assistance to Andrea Kovacs.

This work was supported by grants from the Novo Nordisk Research Foundation, Rigshospitalet, The Danish Heart Association and Svend Andersen Research Foundation.

Z Horvath and S Lee were financed by a state scholarship grant from the School of Ph.D. Studies, Semmelweis University.

Conflict of interest

Authors disclose any and all relationships that could be perceived as real or apparent conflict of interest.

References

- 1 Zeiher AM, Drexler H, Wollschlaeger H, Saubier B, Just H. *Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium.* J Am Coll Cardiol. 1989 Nov;14:1181-90.
- 2 Kemp HG. *Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms.* Am J Cardiol. 1973 Sep;32:375-6.
- 3 Jespersen L, Hvelplund A, Abildstrøm SZ *et al.* *Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events.* Eur Heart J. 2012 Mar;33:734-44.

- 4 Cannon RO, Epstein SE. "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. *Am J Cardiol.* 1988 Jun;61:1338-43.
- 5 Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. *Circulation.* 1991 Feb;83:391-401.
- 6 Egashira K, Inou T, Hirooka Y et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. *J Clin Invest.* 1993 Jan;91:29-37.
- 7 Quyyumi AA, Dakak N, Andrews NP et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. *J Clin Invest.* 1995 Apr;95:1747-55.
- 8 Bencze J, Kiss RG, Toth-Zsomboki E et al. Inverse correlation between coronary blood flow velocity and sICAM-1 level observed in ischemic heart disease patients. *Atherosclerosis.* 2006 Sep;188:142-9.
- 9 Agrawal S, Mehta PK, Bairey Merz CN. Cardiac Syndrome X: update 2014. *Cardiol Clin.* 2014 Aug;32:463-78.
- 10 Horváth Z, Csuka D, Vargova K et al. Elevated C1rC1sC1inh levels independently predict atherosclerotic coronary heart disease. *Mol Immunol.* 2013 May;54:8-13.
- 11 Walport MJ. Complement. First of two parts. *N Engl J Med.* 2001 Apr;344:1058-66.
- 12 Walport MJ. Complement. Second of two parts. *N Engl J Med.* 2001 Apr;344:1140-4.
- 13 Endo Y, Matsushita M, Fujita T. The role of ficolins in the lectin pathway of innate immunity. *Int J Biochem Cell Biol.* 2011 May;43:705-12.
- 14 Trenk D, Kristensen SD, Hochholzer W, Neumann FJ. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. *Thromb Haemost.* 2013 May;109:834-45.
- 15 Garred P, Honoré C, Ma YJ, Munthe-Fog L, Hummelshøj T. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. *Mol Immunol.* 2009 Sep;46:2737-44.
- 16 Garred P, Honoré C, Ma YJ et al. The genetics of ficolins. *J Innate Immun.* 2010;2:3-16.
- 17 Kilpatrick DC, Chalmers JD. Human L-ficolin (ficolin-2) and its clinical significance. *J Biomed Biotechnol.* 2012;2012:138797.
- 18 Matsushita M. Ficolins in complement activation. *Mol Immunol.* 2013 Aug;55:22-6.
- 19 Pavlov VI, Skjoedt MO, Siow Tan Y, Rosbjerg A, Garred P, Stahl GL. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. *Circulation.* 2012 Oct;126:2227-35.

- 20 Munthe-Fog L, Hummelshøj T, Hansen BE *et al.* *The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels.* Scand J Immunol. 2007 Apr;65:383-92.
- 21 Munthe-Fog L, Hummelshøj T, Ma YJ *et al.* *Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state.* Mol Immunol. 2008 May;45:2660-6.
- 22 Csuka D, Munthe-Fog L, Skjoedt MO *et al.* *A novel assay to quantitate MASP-2/ficolin-3 complexes in serum.* J Immunol Methods. 2013 Jan;387:237-44.
- 23 Skjoedt MO, Hummelshøj T, Palarasah Y *et al.* *A novel mannose-binding lectin/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation.* J Biol Chem. 2010 Mar;285:8234-43.
- 24 Hein E, Honoré C, Skjoedt MO, Munthe-Fog L, Hummelshøj T, Garred P. *Functional analysis of Ficolin-3 mediated complement activation.* PLoS One. 2010;5:e15443.
- 25 Palarasah Y, Skjoedt MO, Vitved L, Andersen TE, Skjoedt K, Koch C. *Sodium polyanethole sulfonate as an inhibitor of activation of complement function in blood culture systems.* J Clin Microbiol. 2010 Mar;48:908-14.
- 26 Mellbin LG, Hamsten A, Malmberg K *et al.* *Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.* Diabetes Care. 2010 Nov;33:2451-6.
- 27 Siezenga MA, Shaw PK, Daha MR, Rabelink TJ, Berger SP. *Low Mannose-Binding Lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort study.* Cardiovasc Diabetol. 2011;10:60.
- 28 Keller TT, van Leuven SI, Meuwese MC *et al.* *Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women.* Arterioscler Thromb Vasc Biol. 2006 Oct;26:2345-50.
- 29 Frauenknecht V, Thiel S, Storm L *et al.* *Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases.* Clin Exp Immunol. 2013 Jul;173:112-20.
- 30 Schoos MM, Munthe-Fog L, Skjoedt MO *et al.* *Association between lectin complement pathway initiators, C-reactive protein and left ventricular remodeling in myocardial infarction-a magnetic resonance study.* Mol Immunol. 2013 Jul;54:408-14.
- 31 Maseri A, Crea F, Kaski JC, Crake T. *Mechanisms of angina pectoris in syndrome X.* J Am Coll Cardiol. 1991 Feb;17:499-506.
- 32 Dollard J, Kearney P, Clarke G, Moloney G, Cryan JF, Dinan TG. *A prospective study of C-reactive protein as a state marker in Cardiac Syndrome X.* Brain Behav Immun. 2015 Jan;43:27-32.
- 33 Vane JR, Anggård EE, Botting RM. *Regulatory functions of the vascular endothelium.* N Engl J Med. 1990 Jul;323:27-36.

- 34 Tousoulis D, Davies GJ, Asimakopoulos G *et al.* *Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X)*. Clin Cardiol. 2001 Apr;24:301-4.
- 35 Suzuki H, Takeyama Y, Koba S, Suwa Y, Katagiri T. *Small vessel pathology and coronary hemodynamics in patients with microvascular angina*. Int J Cardiol. 1994 Feb;43:139-50.
- 36 Xiao X, Ma B, Dong B *et al.* *Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice*. J Autoimmun. 2009 Mar;32:85-93.
- 37 Zhang J, Gerhardinger C, Lorenzi M. *Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy*. Diabetes. 2002 Dec;51:3499-504.
- 38 Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, Bhakdi S. *Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy*. Invest Ophthalmol Vis Sci. 2002 Apr;43:1104-8.
- 39 Krarup A, Thiel S, Hansen A, Fujita T, Jensenius JC. *L-ficolin is a pattern recognition molecule specific for acetyl groups*. J Biol Chem. 2004 Nov;279:47513-9.
- 40 Faro J, Chen Y, Jhaveri P *et al.* *L-ficolin binding and lectin pathway activation by acetylated low-density lipoprotein*. Clin Exp Immunol. 2008 Feb;151:275-83.
- 41 Ma YG, Cho MY, Zhao M *et al.* *Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement*. J Biol Chem. 2004 Jun;279:25307-12.
- 42 Torzewski M, Bhakdi S. *Complement and atherosclerosis-united to the point of no return?* Clin Biochem. 2013 Jan;46:20-5.
- 43 Noris M, Remuzzi G. *Overview of complement activation and regulation*. Semin Nephrol. 2013 Nov;33:479-92.
- 44 Hoffmeister HM, Ehlers R, Büttcher E *et al.* *Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris*. Am J Cardiol. 2002 Apr;89:909-12.
- 45 Lanza GA, Crea F. *Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management*. Circulation. 2010 Jun;121:2317-25.
- 46 Peerschke EI, Yin W, Ghebrehiwet B. *Complement activation on platelets: implications for vascular inflammation and thrombosis*. Mol Immunol. 2010 Aug;47:2170-5.
- 47 Haahr-Pedersen S, Bjerre M, Flyvbjerg A *et al.* *Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primary percutaneous coronary intervention*. J Invasive Cardiol. 2009 Jan;21:13-9.

48 Saevarsdottir S, Oskarsson OO, Aspelund T et al. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. *J Exp Med.* 2005 Jan;201:117-25.

49 Vengen IT, Madsen HO, Garred P, Platou C, Vatten L, Videm V. Mannose-binding lectin deficiency is associated with myocardial infarction: the HUNT2 study in Norway. *PLoS One.* 2012;7:e42113.

Table 1.

| Demographic data | CHD (n = 37) | CSX (n = 18) | HC (n = 54) |
|---|------------------------|------------------------|--------------------------------|
| Age, mean \pm S.D., years | 61.44 \pm 8.69 | 61.08 \pm 8.81 | 35.00 \pm 11.25 ^a |
| Males/females, n (%) | 32 (86.4)/5(13.6) | 9 (50)/ 9 (50) | 21 (39)/ 33 (61) ^c |
| BMI, mean \pm S.D., kg/m ² | 29.06 \pm 5.61 | 28.56 \pm 4.73 | 23.69 \pm 4.60 ^a |
| Risk factors | | | |
| History of tobacco use, n (%) | 28 (75.6) | 8 (44.4) | 6 (11.1) ^a |
| Hypertension, n (%) | 32 (86.4) | 14 (77.7) | 5 (9.26) ^a |
| Diabetes mellitus, n (%) | 17 (45.9) | 3 (16.6) | 0 (0) ^a |
| Hyperlipidemia, n (%) | 17 (45.9) | 7 (38.8) | 2 (3.70) ^a |
| Previous AMI, n (%) | 18 (48.6) ^b | 0 (0) | 0 (0) |
| Previous PCI, n (%) | 19 (51.3) ^b | 0 (0) | 0 (0) |
| Previous CABG, n (%) | 6 (16.2) ^b | 0 (0) | 0 (0) |
| Medication on admission | | | |
| Aspirin, n (%) | 26 (70.27) | 9 (50) | 2 (3.70) ^a |
| Clopidogrel, n (%) | 25 (67.6) | 5 (27.7) | 0 (0) ^a |
| ACE inhibitors, n (%) | 31 (83.7) | 11 (29.7) | 1 (1.85) ^a |

| | | | |
|---------------------------------------|--------------------------|----------------------------|----------------------------|
| Beta blockers, <i>n</i> (%) | 34 (91.9) | 15 (83.3) | 1 (1.85) ^a |
| Lipid-lowering agents, <i>n</i> (%) | 32 (86.4) | 9 (50) | 0 (0) ^a |
| Nitroglycerine/nitrates, <i>n</i> (%) | 9 (24.3) | 5 (27.7) | 0 (0) ^a |
| Laboratory parameters | | | |
| CK, mean ± S.D. (U/l) | 136.94 ± 58.63 | 101.40 ± 44.40 | n.m. |
| LDH, mean ± S.D. (U/l) | 335.23 ± 63.93 | 268.36 ± 139.51 | n.m. |
| Cholesterol, mean ± S.D. (mmol/l) | 4.15 ± 1.03 | 4.66 ± 1.31 | 4.84 ± 0.88 ^c |
| HDL cholesterol, mean ± S.D. (mmol/l) | 0.98 ± 0.20 ^b | 1.29 ± 0.41 | 1.55 ± 0.59 |
| LDL cholesterol, mean ± S.D. (mmol/l) | 2.44 ± 0.90 | 2.53 ± 0.94 | 2.57 ± 0.96 |
| Triglycerides, mean ± S.D. (mmol/l) | 1.58 ± 0.71 | 1.56 ± 0.72 | 0.95 ± 1.01 ^c |
| GOT, mean ± S.D. (U/l) | 25.75 ± 11.29 | 31.18 ± 19.45 ^d | 20.00 ± 5.46 |
| Creatinine, mean ± S.D. (μmol/l) | 74.87 ± 14.70 | 78.83 ± 21.23 | 67.00 ± 12.29 ^c |
| CN, mean ± S.D. (mmol/l) | 5.66 ± 1.46 | 6.66 ± 2.42 | 4.40 ± 1.02 ^a |
| CRP, mean ± S.D. (mg/l) | 3.16 ± 2.23 | 2.49 ± 2.83 | n.m. |
| Fructosamine, mean ± S.D. (μmol/l) | 233.82 ± 41.96 | 236.88 ± 32.57 | n.m. |

Table 1. Demographic parameters. The values in parentheses represent percentages. Values are means ± S.D or *n* (%). Abbreviations: S.D.: standard deviation, CHD: patients with coronary heart disease, CSX: patients with negative coronary angiography, HC: healthy control individuals, BMI: Body mass index, CK, creatine kinase; LDH, lactat-dehydrogenase; AST, aspartate aminotransferase; CN, carbamide; n.m., not measured. Fisher's exact test for the categorical variables, Mann-Whitney test for the continuous variables. Individuals in HC group received ASA and statin for primary prevention of cardiovascular events.

a: significant differences in HC group compared to CSX and CHD groups, $p < 0.01$ respectively

b: significant differences in CHD group compared to CSX and HC groups, $p < 0.05$ respectively

c: significant differences between CHD vs. HC group, $p < 0.05$

d: significant differences between CSX vs. HC group, $p < 0.05$

Table 2.

| | CHD | CSX | HC | p value |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|---|
| TCC, AU/ml | 2.04 (1.54 – 2.46) | 5.45 (3.71 – 7.62) | 1.30 (0.93 – 2.29) | 0.0001 ^a <0.0001 ^b |
| Ficolin-2, $\mu\text{g/ml}$ | 5.20 (3.50 – 7.70) | 3.60 (3.20 – 4.70) | 5.80 (4.20 – 8.0) | 0.052 ^a 0.005 ^b |
| Ficolin-3, $\mu\text{g/ml}$ | 26.80 (18.30 – 37.10) | 17.80 (12.90 – 25.30) | 24.10 (18.20 – 30.10) | 0.016 ^a 0.035 ^b |
| MAP-1, ng/ml | 212.40 (169.80 – 237.60) | 178.60 (123.40 – 253.60) | 194.50 (149.60 – 279.50) | NS |
| Ficolin-3/MASP-2 complex, AU/ml | 87.0 (54.90 – 188.60) | 92.90 (39.40 – 121.70) | 144.90 (89.80 – 336.20) | 0.506 ^a 0.006 ^b |
| Ficolin-3 mediated TCC-deposition, % | 159.70 (72.70 – 203.0) | 67.80 (27.80 – 129.0) | 143.30 (91.90 – 195.30) | 0.037 ^a 0.008 ^b |

Table 2. Serum lectin pathway parameter levels within the patient groups (CHD and CSX) and healthy controls (HC).

The values in parentheses represent 25th-75th percentile. Values are given as medians. Abbreviations: CHD: patients with coronary heart disease, CSX: cardiac syndrome X patients

a: CHD vs. CSX, b: CSX vs. HC

Table 3.

| | CHD | CSX |
|----------------------------------|-------------------------------|-------------|
| | HL +/HL - | HL +/HL - |
| C5b-9, AU/ml | 2.05/2.03 | 5.80/5.10 |
| Ficolin-3 med. TCC-deposition, % | 170.50/81.60 (0.003) | 77.30/51.60 |
| Ficolin-3/MASP-2 complex, AU/ml | 132.60/72.02 (0.013) | 94.40/88.0 |
| Ficolin-2 µg/ml | 6.90/4.60 (0.047) | 3.50/3.60 |
| Ficolin-3 µg/ml | 34.30/18.40 (0.0001) | 19.0/16.70 |
| MAP-1 ng/ml | 227.90/207.70 | 185.0/171.0 |

Table 3. Serum lectin pathway component levels according to presence/absence of hyperlipidemia.

The values in parentheses represent p value. Values are given as medians.

Abbreviations: HL: hyperlipidaemia, CHD: patients with coronary heart disease, CSX: cardiac syndrome X patients

Table 4.

| Correlation between serum triglyceride levels and: | CHD | CSX |
|--|--------------------------|--------------------|
| sC5b-9 | R=0.086 / p=0.691 | R=-0.414 / p=0.098 |
| Ficolin-3 med. TCC-deposition | R=0.424 / p=0.043 | R=-0.098 / p=0.737 |
| Ficolin-3/MASP-2 complex | R=0.426 / p=0.042 | R=-0.143 / p=0.626 |
| Ficolin-2 | R=0.528 / p=0.009 | R=0.055 / p=0.851 |
| Ficolin-3 | R=0.512 / p=0.012 | R=-0.200 / p=0.493 |
| MAP-1 | R=0.449 / p=0.031 | R=0.402 / p=0.154 |

Table 4. Correlation between serum lectin pathway parameter levels and serum triglyceride levels in different patients subgroups.

Values represent the result of Spearman rank correlation analysis.

Abbreviations: CHD: patients with coronary heart disease, CSX: cardiac syndrome X patients

Figure Legends

Figure 1. Correlations between serum lectin pathway components in the CSX group. Figure 1/A: correlation between TCC and FCN3-TCC in the CSX group. Figure 1/B: correlation of ficolin-3/MASP-2 complex level and FCN3-TCC deposition.




Figure 1.